Our previous studies showed that the RGD4C/AAVP‐Grp78‐HSVtk is superior to the conventional RGD4C/AAVP‐CMV‐HSVtk vector in inducing glioblastoma cell killing in vitro as well as GBM growth inhibition in vivo following intravenous administration of vectors carrying the HSVtk, and intraperitoneal injection of GCV (Kia et al, 2012). This evidence concerns the gene HSPA5 and glioblastoma.